No abstract

Background: Tumor lymphocyte infiltrates (e.g. Immunoscore) and systemic inflammatory indices (SII) are highly prognostic in colon cancer but combined assessment is less well studied. The aim of this study was to investigate the prognostic and predictive value of CD8 + tumor-infiltrating lymphocytes (TIL) in combination with SII in patients with resected stage II-III colon cancer (CC).Methods: Patients with stage II-III CC (n¼304) diagnosed between 2008-2016 in our hospital were included. Pan-immune inflammation value (PIV) was calculated as; (neutrophil count  platelet count  monocyte count)/lymphocyte count. The mean density of CD8 + TILs in the periphery and center of the tumor was assessed and dichotomized at the 75 th percentile. Combined inflammation score (CIS) was classified as "high" in patients with high PIV (>median) and low mean CD8 + TIL density, and "low" in the remaining patients.Results: Five year DFS was 71% (78% in stage II, 64% in stage III). CD8 + TIL density was lower in node positive tumors and higher in mismatch repair deficient tumors, no association was observed with age, tumor sidedness or systemic inflammation indices. High PIV (>491), low CD8 + (<46 /mm 2 ) and high CIS were associated with shorter disease-free survival (DFS). In multivariate analysis; age > 65 (vs <65) years (HR: 3.12 95% CI 1.78-5.48 p <0.001), stage 3 (vs. 2) disease (HR: 1.82 95% CI 1.06 3.12 p ¼ 0.029) and high (vs low) CIS (HR: 3.82 95% CI 2.21-6.61 p <0.001) were associated with shorter DFS. Among patients with stage II disease, 78 patients (52%) received adjuvant chemotherapy. Patients with high CIS derived significant benefit from adjuvant chemotherapy (5 yr DFS 100% vs 60%, p¼0.008) while those with low CIS derived no benefit (5 yr DFS 88 vs 89% p¼0,94). (Table ) Conclusions: Combined inflammation score may represent a new prognostic factor for localized colon cancer and predictor of chemotherapy response in patients with stage II disease.Legal entity responsible for the study: The authors.

No abstract

e13583 Background: Previous studies demonstrated increased risk of cancer in systemic autoimmune diseases like rheumatoid arthritis, systemic lupus erythematosus (SLE) and sjögren syndrome due to uncontrolled inflammation. Behçet’s disease (BD) was also reported to be associated with an increased risk of cancer, although data is limited and differences in study designs was an important issue. In this study, we aimed to assess cancer incidence in a large cohort of BD patients and to compare with the data of the Turkish National Cancer Registry (TNCR) in the same age and gender groups. Methods: The study cohort consisted of BD patients of > 18 years old age and without a prior cancer diagnosis who were prospectively recorded in Hacettepe University Vasculitis Center. Data on any cancer was collected from the patient files. Cancer incidence was compared with age- and gender-specific cancer incidence rates of the normal population retrieved from the 2014 Turkish National Cancer Registry (TNCR) data using standardized incidence rates (SIR). Results: Totally 451 adult cases with BD were included in the study. The median age of the cohort was 43 (20-75) and 52.5% of the patients were males. Eleven cancer cases were observed during a median 124 months follow up. Behçet’s Disease was associated with an increase in cancer risk compared to expected counts in the corresponding age and sex group (SIR 2.84, 95% CI 1.50-4.94, p < 0.001). Cancer risk was particularly increased in men (SIR: 5.63, 95% CI: 2.62–10.70, p < 0.001) compared to TNCR data. Patients with papulopustular lesions had a trend towards a decreased risk of cancer (p = 0.060) and patients using azathioprine had a significantly decreased cancer risk (p = 0.031). Conclusions: This study revealed the cancer risk of patients BD was increased approximately three times compared to corresponding age and sex group. Besides the routine care, increased attention for cancer surveillance is required in the follow-up of BD patients.

No abstract